ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 37377403

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.

Facchinetti F and 21 others. Cancer Discov, 2023. Cited by 73 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer. Papers, record 37377403. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37377403

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer.
PubMed
Journal
Cancer Discov
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
73
iCite
Relative citation ratio, by iCite
6.07
iCite
Revised in PubMed
2025-05-30
PubMed

Authors22

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Facchinetti FFrancescohttps://orcid.org/0000-0001-6313-6341
2Hollebecque AAntoinehttps://orcid.org/0000-0003-2869-7551
3Braye FFlorianehttps://orcid.org/0009-0002-3527-6771
4Vasseur DDamienhttps://orcid.org/0000-0001-8787-1498
5Pradat YYoannhttps://orcid.org/0000-0002-4647-5779
6Bahleda RRastislavhttps://orcid.org/0009-0001-8245-0544
7Pobel CCédrichttps://orcid.org/0000-0001-6251-622X
8Bigot LLudovichttps://orcid.org/0009-0009-0820-5370
9Déas OOlivierhttps://orcid.org/0000-0001-7355-3632
10Florez Arango JDJuan Davidhttps://orcid.org/0009-0004-4531-6495

1 to 10 of 22Source PubMed

See all 22 authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Urinary Bladder NeoplasmsMajor topic
Carcinoma, Transitional CellMajor topic
Humans
Neoplasm Recurrence, Local
Protein Kinase Inhibitors
TOR Serine-Threonine Kinases
Class I Phosphatidylinositol 3-Kinases
Phosphatidylinositol 3-Kinases

Source PubMed

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
101044047European Research CouncilInternationalPubMed

Source PubMed

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in37,671,472FGFR Inhibition: Understanding and Overcoming Resistance.https://conductscience.org/library/papers/37671472

Source PubMed

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129,848,605Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.Cancer Discov2018https://conductscience.org/library/papers/29848605PubMed
231,585,938Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.Clin Cancer Res2020https://conductscience.org/library/papers/31585938PubMed
334,250,419Noninvasive Detection of Polyclonal Acquired Resistance to FGFR Inhibition in Patients With Cholangiocarcinoma Harboring FGFR2 Alterations.JCO Precis Oncol2021https://conductscience.org/library/papers/34250419PubMed
431,340,094Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.N Engl J Med2019https://conductscience.org/library/papers/31340094PubMed
528,601,352Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.Eur Urol2017https://conductscience.org/library/papers/28601352PubMed
630,352,907Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.Clin Cancer Res2019https://conductscience.org/library/papers/30352907PubMed
735,030,333Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.Lancet Oncol2022https://conductscience.org/library/papers/35030333PubMed
826,278,805Genomic Characterization of Upper Tract Urothelial Carcinoma.Eur Urol2015https://conductscience.org/library/papers/26278805PubMed
924,476,821Comprehensive molecular characterization of urothelial bladder carcinoma.Nature2014https://conductscience.org/library/papers/24476821PubMed
1022,869,148Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.Oncogene2013https://conductscience.org/library/papers/22869148PubMed

1 to 10 of 36

See all 36 references

Cited by49

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 73 citations.

PMIDTitleJournalYearIn PapersSource
42,724,638Treating T24 cells with erianin restores gefitinib drug sensitivity by regulating MYLK to inhibit EGFR and EMT processes.Am J Cancer Res2026https://conductscience.org/library/papers/42724638PubMed
42,544,574FGFR3-driven gene regulatory network analysis reveals a protumoral role for p63 in luminal bladder tumors.J Clin Invest2026https://conductscience.org/library/papers/42544574PubMed
42,266,656The international and domestic research trends of targeted therapy in bladder cancer: a bibliometric analysis of the past three decades.Front Oncol2026https://conductscience.org/library/papers/42266656PubMed
42,211,755Integrated Genomic and Single-Cell Analysis Reveals Heterogeneity, Prognosis, and Treatment Vulnerability in Urothelial Carcinoma.Hum Mutat2026https://conductscience.org/library/papers/42211755PubMed
42,125,063Design and synthesis of an erdafitinib-based selective FGFR2 degrader.Beilstein J Org Chem2026https://conductscience.org/library/papers/42125063PubMed
42,074,119Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma.Int J Mol Sci2026https://conductscience.org/library/papers/42074119PubMed
41,760,649Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.Nat Commun2026https://conductscience.org/library/papers/41760649PubMed
41,615,925Uralenol, Glycyrol, and Abyssinone II as potent inhibitors of fibroblast growth factor receptor 2 from anti-cancer plants: A deep learning and molecular dynamics approach.PLoS One2026https://conductscience.org/library/papers/41615925PubMed
41,593,746Response to letter to the editor for "Infigratinib low dose therapy is an effective strategy to treat hypochondroplasia".J Bone Miner Res2026https://conductscience.org/library/papers/41593746PubMed
41,514,604FGFR Aberrations in Solid Tumors: Mechanistic Insights and Clinical Translation of Targeted Therapies.Cancers (Basel)2025https://conductscience.org/library/papers/41514604PubMed

1 to 10 of 49

See all 49 cited by

Genes20

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
BCL2L1110,018PubTator's text mininghttps://conductscience.org/library/genes/10018NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
EIF2AK39,451PubTator's text mininghttps://conductscience.org/library/genes/9451NCBI Gene
FGFR12,260PubTator's text mininghttps://conductscience.org/library/genes/2260NCBI Gene
FGFR22,263PubTator's text mininghttps://conductscience.org/library/genes/2263NCBI Gene
FGFR32,261PubTator's text mininghttps://conductscience.org/library/genes/2261NCBI Gene
FGFR42,264PubTator's text mininghttps://conductscience.org/library/genes/2264NCBI Gene
KMT2D8,085PubTator's text mininghttps://conductscience.org/library/genes/8085NCBI Gene
MTOR2,475PubTator's text mininghttps://conductscience.org/library/genes/2475NCBI Gene
NF24,771PubTator's text mininghttps://conductscience.org/library/genes/4771NCBI Gene

1 to 10 of 20

See all 20 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/37377403

GET https://conductscience.org/api/papers/v1/37377403/authors?page=2

API referenceFor AI assistants